New Genmab/Seagen drug will cost up to USD 120,000

This week's FDA approval of cervical cancer drug Tivdak is a historic one for Genmab. Although the company does have other approved drugs on the market – Darzalex, Kesimpta and Tepezza – this marks the first time that the company will market one of its own drugs.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: New Genmab approval shows portfolio potential
For subscribers